['lizbeth]

I think we all can agree this study is extremely flawed. Who would give early breast cancer patients Herceptin and a taxane - and state it causes minimal side effects?

Sarah, you also make excellent points. I would rather see a study of Perjeta & Herceptin, with a reduction in the taxane (or less toxic chemo linked to a targeted therapy).

The concept that Lani showed - of multiple targeted therapies has not sunk in yet.

The industry is too static, holding on to toxic treatments.

We have Kadcyla, now lets us see a milder ADC plus multiple targeted therapies that were determined with functional or genetic profiling. These techniques must be followed with improved follow up and better imaging.

Once again the question should not be how many women can be treated with chemo to get the best numbers. It should be which women must be treated, and which can be spared from the toxicities.